Search

CYT007-TNFQb

The vaccine should allow for administration of low amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules. … CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.

Rupintrivir

Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus. … Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections.

DP-VPA

DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure

Incadronic acid

[A14426,A14431,A14427,A202769] Incadronic acid was first described in the literature in 1991.[A202289] … Along with being investigated to treat hypercalcemia of malignancy,[A202862] it has also been investigated in the treatment of myeloma, leukemia, and other cancers.

PPI-2458

In preclinical studies to date, PPI-2458 has demonstrated the potent pharmacologic activity of this class of compounds while displaying an improved pharmacokinetic and toxicity profile. … This class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in diseases

Elafin

The excellent tolerability of Elafin in human subjects was demonstrated in a Phase I clinical single dose escalating study. … Elafin is a human protein that is produced naturally in the skin, lung and breast, protecting the respective tissue from destruction by the immune system.

Fontolizumab

Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.

Enzastaurin

Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of

Methylisothiazolinone

Glyceryl laurate